Catalog No.
Product Name
Application
Product Information
Citations
-
HBV Inhibitor
Inarigivir ammonium is a potent HBV inhibitor that functions as a RIG-I (Retinoic acid-inducible gene-I) agonist, stimulating the innate immune response to combat hepatitis B virus infection. This compound has demonstrated effectiveness in significantly reducing liver HBV DNA levels in transgenic mouse models. Due to its mechanism of action, Inarigivir ammonium is positioned as a valuable tool for research in antiviral therapies and the study of hepatitis B virus dynamics. -
Anti-HBV Agent
Chamaechromone is a biflavonoid compound derived from the roots of Stellera chamaejasme L. It exhibits potent anti-hepatitis B virus (HBV) activity by inhibiting the secretion of hepatitis B surface antigen (HBsAg). This compound is valuable for research in virology, particularly in the study of HBV infection and potential therapeutic interventions. Additionally, Chamaechromone displays insecticidal properties, indicating its multifaceted biological activities. -
HBV Inhibitor
5-O-(E)-p-Coumaroylquinic acid is a quinic acid derivative that serves as a potent inhibitor of hepatitis B virus (HBV). This compound exhibits significant antiviral activity, making it a valuable tool for research into HBV pathogenesis and therapeutic strategies. Its unique structural properties may provide insights into the development of novel antiviral agents targeting viral replication. -
HBV Inhibitor
Schisantherin C is a potent inhibitor of hepatitis B virus (HBV) with demonstrated efficacy in reducing hepatocyte secretions of HBsAg and HBeAg by 59.7% and 34.7%, respectively, at a concentration of 50 μg/mL. This compound holds potential for research applications aimed at understanding HBV pathogenesis and developing effective antiviral therapies. -
HBV Inhibitor
ALG-001075 functions as a capsid assembly modulator (CAM) and serves as an orally active inhibitor of hepatitis B virus (HBV). This compound effectively inhibits HBV DNA production, along with extracellular HBsAg/HBeAg and intracellular HBV RNA in primary human hepatocytes. In the AAV-HBV mouse model, ALG-001075 demonstrates significant reductions in circulating HBV DNA. It is valuable for research applications focused on chronic hepatitis B (CHB). -
HBV Inhibitor
SAG-524 is a highly effective small molecule inhibitor targeting hepatitis B virus (HBV) replication. It demonstrates significant antiviral activity, reducing HBV-DNA and HBsAg levels in supernatants of HepG2.2.15 cells, with IC50 values of 0.92 nM and 1.4 nM, respectively. SAG-524 is valuable for research focused on HBV biology and therapeutic development for liver diseases associated with viral infections. -
HBV Capsid Inhibitor
AB-836 is an orally active inhibitor of the hepatitis B virus (HBV) capsid, targeting the HBV core protein to impede viral replication. This compound is valuable for research focused on chronic hepatitis B, offering insights into antiviral strategies and mechanisms of HBV pathogenesis. Researchers can utilize AB-836 to explore its potential therapeutic applications in HBV-related studies. -
HBV Inhibitor
Xalnesiran sodium is a small interfering RNA (siRNA) designed to inhibit hepatitis B virus (HBV) replication. It provides a valuable tool for researching chronic HBV infections and understanding the virus's biology. This compound is particularly relevant in studies aimed at developing therapeutic strategies for managing HBV-related diseases. -
HBV Inhibitor
CCC-0975 is a selective inhibitor of the hepatitis B virus (HBV), demonstrating an EC50 of 10 μM. This compound effectively disrupts the conversion of relaxed circular DNA (rcDNA) to covalently closed circular DNA (cccDNA), leading to a reduction in both cccDNA and its precursor, deproteinized rcDNA (DP-rcDNA), without inducing their degradation within the cell. CCC-0975 is a valuable tool for research focused on chronic hepatitis B and its associated mechanisms. -
Anti-HBV Inhibitor
IR415 is a potent inhibitor of hepatitis B virus (HBV) replication, primarily functioning by blocking the activity of the HBx protein. It exhibits a high affinity for HBx with a dissociation constant (Kd) of 2 nM, effectively disrupting HBV-mediated RNA interference suppression. By reversing the inhibitory effects of HBx on the dicer endoribonuclease, IR415 serves as a valuable reagent for research into antiviral strategies and mechanisms of HBV pathology. -
HBV Inhibitor
Torcitabine, also known as 2'-Deoxy-L-cytidine, is an antiviral compound targeting hepatitis B virus (HBV) replication. It demonstrates significant inhibitory activity against HBV, making it a valuable agent in the research and development of treatments for chronic HBV infections. Its mechanism of action involves incorporation into viral DNA, effectively disrupting viral replication and propagation. -
Anti-HBV Agent
Alamifovir is a purine nucleotide analogue proagent that targets hepatitis B virus (HBV) with potent antiviral activity. It demonstrates efficacy against both wild type and lamivudine-resistant strains of HBV, effectively inhibiting viral replication. Alamifovir is employed in research applications focused on the treatment and management of HBV infections. -
HBV Inhibitor
CYP1A1 inhibitor 8a is a selective inhibitor of the CYP1A1 enzyme, showing over 10-fold selectivity for its target and greater than 100-fold selectivity against other CYP1 subfamily enzymes. This compound effectively antagonizes benzo[a]pyrene (B[a]P)-mediated activation of the aryl hydrocarbon receptor (AhR) in yeast models and demonstrates protective effects against CYP1A1-mediated B[a]P cytotoxicity in human cells. Due to its significant inhibitory properties, CYP1A1 inhibitor 8a holds promise as a potential agent for cancer chemoprevention. -
HBV Inhibitor
Neochlorogenic acid methyl ester is an HBV inhibitor that functions as a selective inducer of quinone reductase (EC50 = 6.7 μM) while demonstrating potent hydroxyl radical scavenging activity (EC50 = 0.81 μM). This compound plays a critical role in antioxidant defense by donating electrons or hydrogen atoms to neutralize hydroxyl radicals, thereby promoting carcinogen detoxification. Neochlorogenic acid methyl ester is utilized in research investigating antioxidant damage and metabolic detoxification, particularly within the contexts of cancer chemotherapy and diseases related to oxidative stress. This compound is derived from the flower buds of *L. japonica*. -
Anti-HBV Compound
Isothiafludine is an orally active non-nucleosidic compound that targets hepatitis B virus (HBV) replication. It functions by inhibiting the encapsidation of pregenomic RNA, thereby effectively reducing viral replication. Isothiafludine is utilized in research focused on HBV and has potential applications in the development of therapeutic strategies against hepatitis B infections. -
HBV Capsid Assembly Modulator
VNRX-9945 is a potent capsid assembly modulator targeting Hepatitis B Virus (HBV) with an EC50 of 2.6 nM. It exhibits broad antiviral activity against multiple HBV genotypes in vitro, demonstrating its effectiveness in diverse biological contexts. Additionally, VNRX-9945 shows favorable pharmacokinetic properties across various species and has demonstrated significant antiviral efficacy in adeno-associated virus mouse models of HBV infection, making it a valuable tool for HBV research and therapeutic development. -
HBV Inhibitor
Tiviciclovir is a guanosine analog that acts as a selective inhibitor of hepatitis B virus (HBV). Its primary mechanism involves interfering with viral replication, making it a valuable tool in the study of HBV-associated diseases. This compound is primarily utilized in research focused on antiviral therapy and the development of treatments for chronic hepatitis B infections. -
HBV Inhibitor
2'-Deoxy-L-adenosine is a potent inhibitor of hepatitis B virus (HBV) replication, targeting the viral polymerase with high specificity and selectivity. This compound functions as a synthon for modified oligodeoxyribonucleotides, making it a valuable tool for research focused on HBV and related hepatotropic viruses, including woodchuck and duck hepatitis viruses. Its ability to interfere with viral replication positions it as a significant reagent in studies aimed at understanding and developing therapies for HBV infections. -
Anti-HBV Agent
Glycosmisic acid is a natural compound that exhibits anti-hepatitis B virus (HBV) activity. It is employed in research related to viral infections, particularly in studies aimed at understanding and developing therapeutic strategies against HBV. This compound may also serve as a valuable tool for investigating the molecular mechanisms underlying HBV pathogenesis. -
HBV Inhibitor
Besifovir Dipivoxil maleate is a potent HBV inhibitor acting as an oral proagent of LB80317. It demonstrates significant efficacy in suppressing hepatitis B virus (HBV) DNA in both treatment-naive and lamivudine-resistant chronic hepatitis B (CHB) patient populations. This compound is valuable for research into therapeutic strategies for managing chronic hepatitis B infections. -
HBV Capsid Assembly Modulator
SHR5133 is a potent HBV capsid assembly modulator that functions through the inhibition of hepatitis B virus (HBV) capsid assembly. Demonstrating an EC50 of 26.6 nM, SHR5133 effectively reduces HBV DNA levels. This compound is primarily utilized in research applications focused on HBV infection and therapeutic development. -
Anti-HBV Agent
Firzacorvir is a cyclic sulfamide compound that targets and modulates the hepatitis B virus (HBV) core protein. It exhibits significant anti-HBV activity with an EC50 of less than 1 μM. This reagent is essential for research applications focused on the treatment and management of HBV infections. -
HBV Inhibitor
HBV-IN-46 is a potent inhibitor of Hepatitis B virus (HBV) S-antigen, demonstrating an EC50 value of 2.6 nM. This active metabolite is valuable for research related to HBV infection and presents a promising tool in the development of antiviral therapies targeting HBV. Its specificity and efficacy make it a useful reagent for studying viral replication and host-pathogen interactions in HBV-related research. -
HBV Modulator
HBV-IN-17 is a potent modulator of Hepatitis B Virus (HBV) capsid assembly, exhibiting an effective concentration (EC50) of 511 nM. This compound targets the viral capsid formation, disrupting the assembly process critical for HBV replication. It is useful in research applications focused on understanding HBV biology and developing potential therapeutics for HBV infection. -
HBV Capsid Assembly Modulator
BA38017 is a potent modulator of HBV core protein assembly, specifically targeting the hepatitis B virus (HBV) replication process. It demonstrates significant inhibitory activity with an EC50 of 0.20 μM, making it a valuable tool for studying HBV biology. This compound is essential for research applications focused on understanding HBV pathogenesis and evaluating potential therapeutic strategies against hepatitis B infection. -
HBV Inhibitor
HBV-IN-43 is a potent inhibitor of Hepatitis B Virus (HBV) replication. This compound demonstrates strong antiviral activity by targeting key viral processes, making it a valuable tool for research into HBV pathogenesis and therapeutic strategies. Its efficacy in inhibiting HBV provides insights into the development of antiviral therapies for Hepatitis B infection. -
Anti-HBV/HDV Agent
Elebsiran is a small interfering RNA (siRNA) that targets and degrades hepatitis B virus (HBV) and hepatitis D virus (HDV) RNA transcripts. This agent significantly reduces HBV surface antigen (HBsAg) levels and viral load, indicating its potent antiviral activity. By binding to the asialoglycoprotein receptor (ASGPR) on liver cells via the GalNAc ligand, Elebsiran enables liver-targeted delivery while ensuring improved liver safety. This reagent is valuable for research focused on chronic HBV and HDV infections. -
HBV Fragment
HBV Seq1 aa:63-71 is a peptide fragment derived from the hepatitis B virus. This specific sequence is instrumental in studying viral protein structure and function, particularly in the context of immune response and vaccine development. Its application extends to investigations of HBV pathogenesis and potential therapeutic targets within the viral lifecycle. -
HBV
Ozisiran is a small interfering RNA (siRNA) that targets hepatitis B virus (HBV) RNA transcripts, leading to a reduction in viral load. This compound exhibits potent antiviral activity, making it a valuable tool for research into HBV pathogenesis and therapeutic interventions. Its application in studies of antiviral mechanisms can enhance understanding of HBV infection and facilitate the development of novel antiviral strategies. -
HBV Inhibitor
HBV-IN-41 is a potent inhibitor of the Hepatitis B Virus (HBV), exhibiting a remarkable EC50 of 0.027 μM. This orally active compound effectively targets viral replication, making it a valuable tool for research into HBV pathogenesis and potential therapeutic interventions. Its efficacy positions it as a significant reagent for studies aimed at developing new antiviral strategies against HBV. -
Anti-HBV Agent
Z060228 is a capsid-targeting anti-HBV agent that inhibits hepatitis B virus (HBV) DNA replication. It demonstrates significant antiviral activity in HepG2.2.15 cell supernatants, making it a valuable tool for HBV research. This compound is useful for studies focused on HBV replication mechanisms and the development of therapeutic strategies against hepatitis B virus infections. -
HBV Inhibitor
Valtorcitabine dihydrochloride is a prodrug of L-deoxycytidine with targeted activity against hepatitis B virus (HBV). It functions as an HBV inhibitor, effectively reducing viral replication and promoting antiviral responses. This compound is primarily utilized in research focusing on HBV infection and the development of therapeutic strategies for managing viral hepatitis. -
Anti-HBV Agent
LPRP-Et-97543 is a potent anti-HBV agent targeting multiple HBV promoters. It effectively reduces Core, S, and preS promoter activities while exhibiting no impact on the X promoter. This compound is suitable for research into both acute and chronic hepatitis B virus infections, making it a valuable tool for studying viral pathogenesis and potential therapeutic interventions. -
Anti-HBV Agent
Junceellolide C is a transcription inhibitor targeting cccDNA, effectively impeding HBV DNA replication. It demonstrates significant reductions in supernatant HBV RNA, with EC50 values of 5.19 μM and 3.52 μM in HepAD38 cells. This compound is recognized for its potent anti-HBV activity, making it a valuable tool for research into therapeutic strategies against hepatitis B virus infections. -
HBV Inhibitor
AT-61 is a non-nucleoside inhibitor that targets Hepatitis B virus (HBV) replication. It disrupts the formation of the capsid necessary for pre-genomic RNA, leading to the generation of empty capsids. This compound demonstrates efficacy against drug-resistant HBV mutant strains and is suitable for research focused on HBV infection mechanisms and therapeutic strategies. -
HBV Inhibitor
Xalnesiran is a small interfering RNA (siRNA) specifically designed to inhibit hepatitis B virus (HBV) replication. By targeting and degrading HBV RNA, it plays a crucial role in reducing viral load and the associated liver pathology. Xalnesiran is valuable for research applications focused on chronic hepatitis B treatment strategies and the investigation of RNA interference mechanisms in viral infections. -
HBV Inhibitor
Glaziovine is an antiviral compound derived from Hypserpa nitida, specifically targeting hepatitis B virus (HBV). It demonstrates potent inhibitory activity against HBV, effectively suppressing the secretion of hepatitis B virus surface antigen (HBsAg) in Hep G2.2.15 cells, with an IC50 value of 8 nM. This reagent is valuable for research into antiviral therapies and the mechanisms of HBV infection. -
HBV CpAM
HBV-IN-18 is an HBV capsid assembly modulator (CpAM) that selectively targets the Hepatitis B virus capsid. It demonstrates a biological activity with an EC50 value of 2790 nM, indicating its potential in inhibiting viral assembly. This compound is applicable in research focused on understanding Hepatitis B virus biology and developing antiviral therapies. -
HBV Inhibitor
Oxynitidine is an HBV inhibitor that demonstrates potent activity against Hepatitis B virus DNA replication, with an ID50 of 30.8 µg/mL. This compound serves as a valuable tool for investigating viral infections and can be utilized in the development of therapeutic interventions targeting HBV. -
HBV/HDV Inhibitor
HBV/HDV-IN-3 is a dual inhibitor targeting Hepatitis B Virus (HBV) and Hepatitis D Virus (HDV), demonstrating an effective EC50 of less than 50 nM against HBV. This compound shows significant antiviral activity and is suitable for research applications focused on the development of therapeutics for HBV and HDV infections. Its effectiveness in inhibiting both viruses makes it a valuable tool for exploring antiviral strategies. -
HBV Inhibitor
AB-506 is an orally bioavailable inhibitor of hepatitis B virus (HBV) replication that targets the viral core protein. By binding to the HBV core protein, AB-506 facilitates capsid assembly and inhibits the encapsidation of HBV pgRNA. This compound is intended for use in research related to chronic hepatitis B (CHB) and provides a valuable tool for studies on viral replication mechanisms and potential therapeutic interventions. -
HBV Capsid Inhibitor
(S)-Canocapavir is an isomer of the antiviral agent Canocapavir, specifically targeting the HBV core protein. It functions as an HBV capsid inhibitor by binding to the hydrophobic pocket at the dimer-dimer interface of the HBV core protein (HBc). This binding promotes the intracellular accumulation of nonfunctional HBV capsids, thereby disrupting viral replication and interfering with the interaction between HBc and the HBV large surface protein. (S)-Canocapavir is relevant for research into hepatitis B virus (HBV) infection and its associated pathologies. -
HBV cccDNA Reducer
HBV-IN-25 is a potent HBV cccDNA reducer with demonstrated oral bioavailability. It exhibits anti-HBeAg potency and anti-HBV activity, with IC50 values of 0.58 μM and 1.15 μM, respectively. HBV-IN-25 possesses excellent aqueous solubility (LYSA > 452 μg/mL) and favorable pharmacokinetic properties, with no observed cellular toxicity. This compound is suited for research applications focused on hepatitis B virus infection and its associated pathologies. -
Anti-HBV Drug
Sanggenol P is a flavonoid with demonstrated anti-hepatitis B virus (HBV) activity, specifically targeting HBV-infected HepG2.2.15 cell lines in vitro. This compound may serve as a valuable tool in the research of HBV-related therapies and the development of antiviral strategies. Its potential role in inhibiting HBV replication highlights its relevance for further studies in hepatology and virology. -
HBV Fragment
HBV Seq1 aa:18-27 is a peptide fragment derived from the hepatitis B virus (HBV) core antigen, specifically representing amino acids 18 to 27. This fragment is valuable for research applications focused on HBV immune response, vaccine development, and diagnostic assays. Its use in studies can aid in the understanding of HBV pathogenesis and potential therapeutic strategies. -
HBV/HDV Inhibitor
HBV/HDV-IN-4 hydrochloride is a dual inhibitor targeting both Hepatitis B virus (HBV) and Hepatitis D virus (HDV), demonstrating potent activity with an EC50 of less than 50 nM against HBV. This compound serves as a valuable tool for investigating therapeutic strategies in viral hepatitis research and offers potential for the development of antiviral agents against these challenging infections. -
HBV RNA Destabilizer
AB-452 is a dihydroquinolizinone (DHQ) analogue that functions as a potent HBV RNA destabilizer. It effectively inhibits PAPD5 and PAPD7 proteins in vitro and demonstrates significant in vivo efficacy in chronic HBV mouse models. This compound serves as a valuable tool for the study of hepatitis B virus pathology and therapeutic interventions. -
HBV Inhibitor
Apigenin-4'-α-L-rhamnoside is a potent inhibitor of Hepatitis B virus (HBV) primarily targeting the secretion of HBV surface antigen (HBsAg). This compound has demonstrated significant efficacy in reducing HBsAg levels in HepG2.2.15 cell lines. Its application in research facilitates the exploration of HBV pathogenesis and potential therapeutic strategies for hepatotropic viral infections. -
HBV-DNA Inhibitor
Oleana-2,12-dien-28-oic acid is a potent HBV-DNA inhibitor that also targets HBsAg and HBeAg. This compound demonstrates significant antiviral activity, making it a valuable tool for studying hepatitis B virus infections. It is suitable for research applications focused on the mechanisms of HBV replication and potential therapeutic interventions. -
HBV Inhibitor
(-)-Carbovir is a potent inhibitor of Hepatitis B virus (HBV) replication. It exhibits antiviral activity by specifically targeting and interfering with HBV polymerase, thereby disrupting viral nucleic acid synthesis. This compound is primarily used in research contexts focused on developing therapeutic strategies for HBV infections and understanding the mechanisms of viral resistance.
